Triple-negative breast cancer lacks the expression of estrogen, progesterone and HER2 receptors, and so it makes it unresponsive for standard hormonal therapies targeting HER2.

Fast Track Designation for LP-184 recognizes TNBC as a serious condition impacting approximately 29,000 patients annually in the US, with over 50% of patients relapsing within 3-5 years.

ZEST included patients with stage I-III triple negative breast cancer (TNBC), or BRCA -mutated HER2-BC. Testing for ctDNA-based MRD began any time after the end of definitive treatment, and those ...

The retrospective study included 1532 patients with stage I-III TNBC who received neoadjuvant therapy between 2000 and 2023 at 12 European centers. Of these patients, 733 (48%) had a pCR.

Key Takeaways Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The ...

VERITAC-2 This trial was emblematic of the rising importance of biomarker testing in cancer care, a theme seen across ASCO 2025. PROTACs are often compared with SERDs, which enable ER degration ...

Neoadjuvant chemotherapy (NACT) use in triple-negative breast cancer (TNBC) increased from 19.1% to 56.4% between 2010 and 2021, with pathologic complete response (pCR) rates rising from 19.6% to ...

More information: KeJing Zhang et al, A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer, Cell Chemical Biology (2024).

More than 10% of new triple-negative breast cancer cases could be avoided if women breastfed or pumped for longer than 6 months, according to results of a retrospective analysis.Between 3,000 and ...